Foster City, CA, Hangzhou and Shanghai, China, Aug 10, 2021 – (ACN Newswire) – Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, today announced the successful dosing of the first patient in a Phase I clinical study of APL-102 in patients with advanced solid tumors. The Phase I trial is designed to assess the safety, tolerability and pharmacokinetics of APL-102 delivered via an oral capsule.

“APL-102 is an internally discovered and developed tyrosine kinase inhibitor targeting multiple oncogenic drivers, and we are excited about advancing it for clinical testing to explore its potential for treating a number of solid tumors;” said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. “APL-102 is the first of several novel assets planned for clinical development to further expand Apollomics’ clinical pipeline in oncology.”

About APL-102

APL-102 is an oral, small molecule multi kinase inhibitor (MTKi) targeting several key oncogenic drivers. APL-102 inhibits several receptor tyrosine kinases (RTKs), including: angiogenesis via vascular endothelial growth factor receptors (VEGFRs), mitogen-activated protein kinase (MAPK) pathway via B-RAF and C-RAF; and colony stimulating factor 1 receptor (CSF1R).

Preclinical studies have demonstrated broad and potent antitumor activity in patient-derived xenograft mouse models of liver, breast, colorectal, gastric, esophageal and lung cancers. APL-102 has also shown favorable preclinical pharmacokinetic (PK) and safety profiles with no serious off-target activity observed. APL-102 has the potential to be used as a single agent or in combination with other oncology agents.

Apollomics retains worldwide rights to APL-102.

About Apollomics Inc.

Apollomics Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting agents and immuno-oncology agents. The Company’s product pipeline has several programs at different stages of development, including novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Apollomics has operating entities in Foster City, Ca., USA, Hangzhou and Shanghai, China. For more information, please visit www.apollomicsinc.com.

Contact information of Apollomics:

Investor Contact:

Wilson W. Cheung

Chief Financial Officer

(650) 209-4436

[email protected]

U.S. Media Contact:

Remy Bernarda

Corporate Communications

(415) 203-6386

[email protected]

China Media Contact:

Porda Havas International Finance Communications Group

Kelly Fung

General Manager

(852) 3150 6763

[email protected]

Phoenix Fung

Vice President

(852) 3150 6773

[email protected]


Topic: Press release summary



Source: Apollomics, Inc.


Sectors: Clinical Trials


http://www.acnnewswire.com


From the Asia Corporate News Network

Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.




Apollomics, Inc.
May 20, 2021 13:36 HKT/SGT

APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH
Mar 9, 2021 10:35 HKT/SGT

Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer
Mar 4, 2021 11:30 HKT/SGT

APOLLOMICS, INC ANNOUNCES SUCCESSFUL ENROLLMENT OF FIRST PATIENT INTO PHASE 1 CLINICAL TRIAL OF APL-106 (UPROLESELAN INJECTION) IN CHINA
Feb 12, 2021 13:00 HKT/SGT

Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
Feb 11, 2021 11:00 HKT/SGT

Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China
Feb 10, 2021 10:10 HKT/SGT

Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors
Feb 3, 2021 06:00 HKT/SGT

Two Immigrants, One Unique Plan For A Biopharma
Jan 7, 2021 20:10 HKT/SGT

APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
More news >>

Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102
Source:
Source 1

LEAVE A REPLY

Please enter your comment!
Please enter your name here